EU and US could reach trade deal this weekend - Reuters
Richard Byrd, Executive Vice President and President of Interventional at Becton Dickinson & Co (NYSE:BDX), recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Byrd sold 1,940 shares of common stock on March 12, 2025, at a price of $224.91 per share. This transaction amounted to a total of $436,325. Following the sale, Byrd retains ownership of 7,411 shares in the company. The stock, which has maintained dividend payments for 55 consecutive years and currently yields 1.86%, is trading near its 52-week low. According to InvestingPro analysis, BDX appears to be undervalued based on its Fair Value estimates. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which Byrd adopted in December 2024. With a beta of 0.38, BDX typically exhibits low price volatility, making it an interesting consideration for value investors. For comprehensive analysis and additional insights, including 12 more exclusive ProTips, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Becton Dickinson (BD) announced a plan to separate its Biosciences and Diagnostic Solutions business, aiming to enhance strategic focus and shareholder value. The board of directors unanimously approved the separation, which is expected to position BD as a leader in medical technology and allow the separated business to thrive as a standalone entity in life sciences. Additionally, activist investor Starboard Value has acquired a stake in BD, advocating for the sale of its life sciences division, which has generated investor interest. In terms of shareholder governance, BD’s recent annual meeting saw the election of all board nominees and the ratification of Ernst & Young as the independent auditor.
Furthermore, BD declared a quarterly dividend of $1.04 per share and authorized the repurchase of up to 10 million shares, reflecting its commitment to shareholder returns. Piper Sandler analysts have raised BD’s stock target to $280, maintaining an Overweight rating, and suggested that a spin-off of the Life Sciences division could unlock additional value. These developments indicate a period of strategic transformation and investor engagement for BD, with the potential for significant impact on its operational focus and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.